Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study CR9108963: A 12-month, Randomized, Double-blind, Parallel-group, Placebo and Active-controlled Dose-range Finding Study of the Efficacy and Safety of SB-751689 in Post-menopausal Women With Osteoporosis

NCT00471237 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00471237
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00471237 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study CR9108963: A 12-month, Randomized, Double-blind, Parallel-group, Placebo and Active-controlled Dose-range Finding Study of the Efficacy and Safety of SB-751689 in Post-menopausal Women With Osteoporosis
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Terminated
Start date
May 14, 2007
Completion date
December 26, 2008
Enrollment
564 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

osteoporosis